Hexal AG Founders Plan to Invest 500 Million Euros in German Biotech Companies
Aug. 20 (Bloomberg) -- Andreas and Thomas Struengmann, co- founders of the German generic-drug maker bought by Novartis AG, have earmarked 500 million euros ($737 million) to spend on German biotechnology companies, Manager magazine reported.